`
`Paper No. ___
`Filed: May 31, 2017
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`
`MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
`INC. and AKORN INC.,
`Petitioners,
`
`v.
`
`ALLERGAN, INC.
`Patent Owner.
`
`_____________________________
`
`Case IPR2016-01130
`Patent No. 8,633,162 B2
`_____________________________
`
`PETITIONER MYLAN PHARMACEUTICALS INC.’S MANDATORY
`CHANGE-OF-INFORMATION NOTICES
`
`
`
`
`
`
`
`
`
`
`Case IPR2016-01130
`Patent 8,633,162 B2
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting
`
`in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”),
`
`hereby submits the following mandatory change-of-information notices in
`
`connection with the petition for inter partes review of U.S. Patent No. 8,633,162
`
`B2, Case IPR2016-01130.
`
`A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Unchanged
`
`C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Revised
`
`
`
`Mylan provides the following updated designation of counsel:
`
`Lead Counsel
`Steven W. Parmelee
`
`Back-Up Counsel
`Michael T. Rosato
`
`USPTO Reg. No. 31,990
`
`USPTO Reg. No. 52,182
`
`WILSON SONSINI GOODRICH &
`
`WILSON SONSINI GOODRICH &
`
`ROSATI
`
`ROSATI
`
`701 Fifth Avenue, Suite 5100
`
`701 Fifth Avenue, Suite 5100
`
`Seattle, WA 98104-7036
`
`Seattle, WA 98104-7036
`
`Tel.: 206-883-2542
`
`Tel.: 206-883-2529
`
`Fax: 206-883-2699
`
`Fax: 206-883-2699
`
`Email: sparmelee@wsgr.com
`
`Email: mrosato@wsgr.com
`
`
`-1-
`
`
`
`
`
`Case IPR2016-01130
`Patent 8,633,162 B2
`
`Back-Up Counsel
`Jad A. Mills
`
`Back-Up Counsel
`Wendy L. Devine
`
`USPTO Reg. No. 63,344
`
`USPTO Reg. No. 61,309
`
`WILSON SONSINI GOODRICH &
`
`WILSON SONSINI GOODRICH &
`
`ROSATI
`
`ROSATI
`
`701 Fifth Avenue, Suite 5100
`
`One Market Street,
`
`Seattle, WA 98104-7036
`
`Spear Tower Floor 33
`
`Tel.: 206-883-2554
`
`San Francisco, CA 94105-1126
`
`Fax: 206-883-2699
`
`Tel.: 858-350-2321
`
`Email: jmills@wsgr.com
`
`Fax: 415-947-2099
`
`Email: wdevine@wsgr.com
`
`D. Electronic Service
`
`Mylan consents to electronic service by email at the email addresses
`
`provided above.
`
`Dated: May 31, 2017
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee
` Reg. No. 31,990
`
`
`
`
`
`-2-
`
`
`
`Case IPR2016-01130
`Patent 8,633,162 B2
`
`CERTIFICATE OF SERVICE
`
`
`
`This is to certify that I caused to be served a true and correct copy of the
`
`foregoing Petitioner Mylan Pharmaceuticals Inc.’s Mandatory Change-of-
`
`Information Notices on this 31st day of May, 2017, on the Patent Owner at the
`
`correspondence address of the Patent Owner as follows:
`
`Dorothy P. Whelan
`Michael Kane
`Susan Morrison Colletti
`Robert M. Oakes
`Jonathan Singer
`Fish & Richardson P.C.
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`Email: IPR13351-0008IP1@fr.com
`Email: IPR13351-0008IP2@fr.com
`Email: IPR13351-0008IP3@fr.com
`Email: IPR13351-0008IP4@fr.com
`Email: IPR13351-0008IP5@fr.com
`Email: IPR13351-0008IP6@fr.com
`Email: PTABInbound@fr.com
`
`And on the remaining petitioners as follows:
`
`
`Gary Speier
`Mark Schuman
`CARLSON, CASPERS, VANDENBURGH,
`LINDQUIST & SCHUMAN, P.A.
`225 South Sixth Street, Suite 4200
`Minneapolois, MN 55402
`Email: gspeier@carlsoncaspers.com
`Email: mschuman@carlsoncaspers.com
`Attorneys for Teva Pharmaceuticals USA, Inc.
`
`
`
`-3-
`
`
`
`Case IPR2016-01130
`Patent 8,633,162 B2
`
`Michael Dzwonczyk
`Azadeh Kokabi
`Travis Ribar
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave., NW
`Washington, DC 20037
`Email: mdzwonczyk@sughrue.com
`Email: akokabi@sughrue.com
`Email: tribar@sughrue.com
`Attorneys for Akorn Inc.
`
`
`
`Dated: May 31, 2017
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee, Lead Counsel
` Reg. No. 31,990
`
`
`
`
`
`-4-
`
`